FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024452581> ?p ?o ?g. }

• W2024452581 endingPage "240" @default.
• W2024452581 startingPage "238" @default.
• W2024452581 abstract "Background: In this phase I/II study, the addition of lapatinib (LAP) was investigated in combination with the sequential use of both approaches TPF induction chemotherapy (ICT) followed by chemoradiation (CRT) in locally advanced larynx or hypopharynx squamous cell carcinoma. Patients and methods: Objectives were to assess maximum tolerated dose, dose-limiting toxicity (DLT) and to recommend a safe dose of LAP when administered with 4 cycles of TPF followed by CRT. Results: Seven male patients were included. Three patients were included in the first cohort, at dose level 1 (LAP 500 mg daily plus TPF). Renal toxicity was observed among these three patients (grade 3 [n = 1], grade 2 [n = 1] and grade 1 [n = 1]), with 1 DLT, leading to treatment interruption in this group. Nephrotoxicity was reversible after stopping LAP and hydration of the patients. In a second cohort of four patients administering docetaxel from the second cycle, 3 more DLTs were observed (grade 2 renal toxicity and grade 3 diarrhea, grade 3 anorexia and grade 3 stomatitis, and grade 4 neutropenia). Based on the occurrence of 4 DLTs at the first dose level of LAP, patient recruitment was closed. Conclusion: These data indicate that LAP cannot be combined safely with full dose TPF." @default.
• W2024452581 created "2016-06-24" @default.
• W2024452581 creator A5002522655 @default.
• W2024452581 creator A5007067879 @default.
• W2024452581 creator A5010064853 @default.
• W2024452581 creator A5011885579 @default.
• W2024452581 creator A5026426994 @default.
• W2024452581 creator A5041435375 @default.
• W2024452581 creator A5045989494 @default.
• W2024452581 creator A5050884991 @default.
• W2024452581 creator A5068150920 @default.
• W2024452581 creator A5080354461 @default.
• W2024452581 creator A5087905831 @default.
• W2024452581 date "2012-11-01" @default.
• W2024452581 modified "2023-09-25" @default.
• W2024452581 title "EORTC 24051: Unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma" @default.
• W2024452581 cites W1838340609 @default.
• W2024452581 cites W1983970003 @default.
• W2024452581 cites W1998417857 @default.
• W2024452581 cites W2005204942 @default.
• W2024452581 cites W2023451378 @default.
• W2024452581 cites W2036363901 @default.
• W2024452581 cites W2062057316 @default.
• W2024452581 cites W2076708539 @default.
• W2024452581 cites W2089257078 @default.
• W2024452581 cites W2092785855 @default.
• W2024452581 cites W2100961085 @default.
• W2024452581 cites W2111442242 @default.
• W2024452581 cites W2112497607 @default.
• W2024452581 cites W2119777146 @default.
• W2024452581 cites W2141592118 @default.
• W2024452581 cites W2146148650 @default.
• W2024452581 cites W2171231486 @default.
• W2024452581 cites W2406213538 @default.
• W2024452581 doi "https://doi.org/10.1016/j.radonc.2012.08.006" @default.
• W2024452581 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22989664" @default.
• W2024452581 hasPublicationYear "2012" @default.
• W2024452581 type Work @default.
• W2024452581 sameAs 2024452581 @default.
• W2024452581 citedByCount "13" @default.
• W2024452581 countsByYear W20244525812013 @default.
• W2024452581 countsByYear W20244525812014 @default.
• W2024452581 countsByYear W20244525812015 @default.
• W2024452581 countsByYear W20244525812016 @default.
• W2024452581 countsByYear W20244525812017 @default.
• W2024452581 countsByYear W20244525812018 @default.
• W2024452581 countsByYear W20244525812019 @default.
• W2024452581 countsByYear W20244525812020 @default.
• W2024452581 countsByYear W20244525812021 @default.
• W2024452581 crossrefType "journal-article" @default.
• W2024452581 hasAuthorship W2024452581A5002522655 @default.
• W2024452581 hasAuthorship W2024452581A5007067879 @default.
• W2024452581 hasAuthorship W2024452581A5010064853 @default.
• W2024452581 hasAuthorship W2024452581A5011885579 @default.
• W2024452581 hasAuthorship W2024452581A5026426994 @default.
• W2024452581 hasAuthorship W2024452581A5041435375 @default.
• W2024452581 hasAuthorship W2024452581A5045989494 @default.
• W2024452581 hasAuthorship W2024452581A5050884991 @default.
• W2024452581 hasAuthorship W2024452581A5068150920 @default.
• W2024452581 hasAuthorship W2024452581A5080354461 @default.
• W2024452581 hasAuthorship W2024452581A5087905831 @default.
• W2024452581 hasConcept C121608353 @default.
• W2024452581 hasConcept C126189478 @default.
• W2024452581 hasConcept C126322002 @default.
• W2024452581 hasConcept C126894567 @default.
• W2024452581 hasConcept C141071460 @default.
• W2024452581 hasConcept C143998085 @default.
• W2024452581 hasConcept C2776694085 @default.
• W2024452581 hasConcept C2777063308 @default.
• W2024452581 hasConcept C2777329042 @default.
• W2024452581 hasConcept C2779786085 @default.
• W2024452581 hasConcept C2781190966 @default.
• W2024452581 hasConcept C29730261 @default.
• W2024452581 hasConcept C530470458 @default.
• W2024452581 hasConcept C71924100 @default.
• W2024452581 hasConcept C90924648 @default.
• W2024452581 hasConceptScore W2024452581C121608353 @default.
• W2024452581 hasConceptScore W2024452581C126189478 @default.
• W2024452581 hasConceptScore W2024452581C126322002 @default.
• W2024452581 hasConceptScore W2024452581C126894567 @default.
• W2024452581 hasConceptScore W2024452581C141071460 @default.
• W2024452581 hasConceptScore W2024452581C143998085 @default.
• W2024452581 hasConceptScore W2024452581C2776694085 @default.
• W2024452581 hasConceptScore W2024452581C2777063308 @default.
• W2024452581 hasConceptScore W2024452581C2777329042 @default.
• W2024452581 hasConceptScore W2024452581C2779786085 @default.
• W2024452581 hasConceptScore W2024452581C2781190966 @default.
• W2024452581 hasConceptScore W2024452581C29730261 @default.
• W2024452581 hasConceptScore W2024452581C530470458 @default.
• W2024452581 hasConceptScore W2024452581C71924100 @default.
• W2024452581 hasConceptScore W2024452581C90924648 @default.
• W2024452581 hasFunder F4320322977 @default.
• W2024452581 hasIssue "2" @default.
• W2024452581 hasLocation W20244525811 @default.
• W2024452581 hasLocation W20244525812 @default.
• W2024452581 hasOpenAccess W2024452581 @default.
• W2024452581 hasPrimaryLocation W20244525811 @default.
• W2024452581 hasRelatedWork W1973241390 @default.

• next